Medicilon(SH:688202)2025-02-27 09:15Financial Performance - The company reported total revenue of 1,041.53 million yuan for the year 2024, a decrease of 23.73% compared to the previous year[3] - The net profit attributable to the parent company was -315.86 million yuan, an increase in loss of 282.65 million yuan year-on-year[5] - The basic earnings per share were -2.36 yuan, compared to -0.26 yuan in the previous year[3] - The weighted average return on equity decreased by 11.80 percentage points to -13.55%[4] - The company’s operating profit and total profit also saw significant declines due to the drop in revenue and inability to adjust costs in the short term[8] Assets and Equity - The total assets at the end of the reporting period were 2,852.29 million yuan, a decrease of 12.66% from the beginning of the period[4] - The equity attributable to the parent company decreased by 14.16% to 2,155.13 million yuan[4] Challenges and Impairments - The company faced significant challenges due to a slowdown in investment and financing in the pharmaceutical industry, leading to a decline in market demand[6] - The company implemented impairment losses on accounts receivable, long-term assets, inventory, and contract orders, negatively impacting net profit[7] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with potential discrepancies in the final report[9]